This is a preview of subscription content, log in via an institution to check access.
References
Parkes, J. D., Zilkha, K. J., Calver, D. M., Knill-Jones, R. P.: Controlled trial of amantadine hydrochloride in Parkinson's disease. Lancet1970 I, 259–262.
Schwab, R. S., England, A. C., Poskanzer, D. C., Young, R. R.: Amantadine in the treatment of Parkinson's disease. J. Amer. med. Ass.208, 1168–1170 (1969).
Vernier, V. G., Harmon, J. B., Stump, J. M., Lynes, Th. E., Marvel, J. P., Smith, D. H.: The toxicologic and pharmacologic properties of amantadine hydrochloride. Toxicol. appl. Pharmacol.15, 642–665 (1969).
Zetler, G.: Cataleptic state and hypothermia in mice, caused by central cholinergic stimulation and antagonized by anticholinergic and antidepressant drugs. Int. J. Neuropharmacol.7, 325–335 (1968).
- Pharmacological differentiation of “nicotinic” and “muscarinic” catalepsy. Neuropharmacology (in the press) (1970).
Author information
Authors and Affiliations
Additional information
I gratefully acknowledge the skilled technical assistance of Mrs. Ruth Scheel.
Rights and permissions
About this article
Cite this article
Zetler, G. Anticataleptic actions of amantadine hydroehloride. Naunyn-Schmiedebergs Arch. Pharmak. 266, 276–278 (1970). https://doi.org/10.1007/BF00997288
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00997288